• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: FERRING PHARMACEUTICALS EUFLEXXA; ACID, HYALURONIC INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

FERRING PHARMACEUTICALS EUFLEXXA; ACID, HYALURONIC INTRAARTICULAR Back to Search Results
Lot Number N10839C
Device Problem Patient-Device Incompatibility (2682)
Patient Problems Bacterial Infection (1735); Pain (1994); Swelling (2091); Arthralgia (2355)
Event Date 02/09/2018
Event Type  Injury  
Event Description
Pt received bilateral euflexxa intra-articular knee injections on (b)(6) 2018.Pt then presented to the clinic on (b)(6) 2018 with a swollen and painful left knee.He had a joint aspiration and was diagnosed with a left knee effusion.Culture was done on left knee joint fluid which resulted in (b)(6).Pt was subsequently placed on antibiotics (clindamycin) as an outpatient and was instructed to call if symptoms worsen.On (b)(6) 2018, the pt returned to the clinic for a f/u routine visit.The care providers did not feel any infection was present at this visit.Therefore, arthrocentesis of left knee (for joint crystals) was performed.Pt also received an intraarticular injection of a steroid into his left knee.He returned to the clinic for f/u on (b)(6) 2018 and he received the 2nd of 3 euflexxa injections for the right knee only.Pt was responding to steroid injection in the left knee and instructed to return to clinic in 1 week to finish series in right knee.Pt presented to the emergency department on (b)(6) 2018, for left knee pain and swelling and was subsequently diagnosed with a septic left knee and admitted for incision and drainage.Picc-line placement, and iv antibiotics.The results of the joint culture from the incision and drainage resulted in (b)(6).Dose or amount: 20 mg milligram(s).Frequency: 3 inj - 1 wk apart.Route: intra-articular.Therapy date: (b)(6) 2018.Diagnosis or reason for use: osteoarthritis.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EUFLEXXA
Type of Device
ACID, HYALURONIC INTRAARTICULAR
Manufacturer (Section D)
FERRING PHARMACEUTICALS
MDR Report Key7299538
MDR Text Key101154254
Report NumberMW5075530
Device Sequence Number1
Product Code MOZ
UDI-Device Identifier55566410001
UDI-Public55566-4100-01
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Pharmacist
Type of Report Initial
Report Date 02/21/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator No Information
Device Expiration Date11/04/2018
Device Lot NumberN10839C
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received Not provided
Initial Date FDA Received02/26/2018
Was Device Evaluated by Manufacturer? No Information
Type of Device Usage N
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Other;
Patient Age74 YR
Patient Weight106
-
-